- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 4th, 2005
When companies partner with one another, it is with the expectation that each has a role to play. Each is expected to perform its part conscientiously and expeditiously. When one partner doesn't hold up its end of the bargain, it results in delays, lost opportunities and, most importantly for companies, lost revenues.
Such is the case with the just-severed deal between pharmaceutical Biovail and nanotech developer Flamel.
|Related News Press|
Nanotech Grants Options September 22nd, 2016
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Nanosciences: Genes on the rack October 21st, 2016
Nanoparticle vaccinates mice against dengue fever October 21st, 2016